TickerFacts.

GRAIL, Inc. (GRAL): Free Cash Flow

Operating cash flow minus capital expenditures for the same annual period and currency, computed by TickerFacts from the filed figures. A simple proxy, not a reported figure; a year without both inputs is left out.

-$299.92M
Year ended 2025-12-31
-$296.16M
Trailing 12 months to 2026-06-30
2023-01-01: -$584.17M2023-12-31: -$608.69M2024-12-31: -$582.36M2025-12-31: -$299.92M-$299.92M
2023-01-01 Free Cash Flow (USD) 2025-12-31
Period endedFree Cash FlowChange YoYSource filing
2025-12-31-$299.92Mn/m2026-03-12, From 2025-01-01
2024-12-31-$582.36Mn/m2026-03-12, From 2024-01-01
2023-12-31-$608.69Mn/a2026-03-12, From 2023-01-01
2023-01-01, Fiscal 2022-$584.17Mn/a2025-03-05, From 2022-01-03

Free Cash Flow at similar companies

Companies with the same SEC industry code (Services-Medical Laboratories), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedFree Cash FlowChange YoY
GRAIL, Inc. (GRAL)2025-12-31-$299.92Mn/m
Biodesix Inc (BDSX)2025-12-31-$23.53Mn/m
BillionToOne, Inc. (BLLN)2025-12-31$15.71Mn/m
Personalis, Inc. (PSNL)2025-12-31-$79.45Mn/m
Fulgent Genetics, Inc. (FLGT)2025-12-31-$124.21Mn/m
Exagen Inc. (XGN)2025-12-31-$14.27Mn/m
Castle Biosciences Inc (CSTL)2025-12-31$28.33M-22.5%
Veracyte, Inc. (VCYT)2025-12-31$126.63M+98.5%
American Shared Hospital Services (AMS)2025-12-31-$4.54Mn/m

Compare GRAL, BDSX, BLLN, PSNL side by side · Screen every company in Services-Medical Laboratories ↗